Skip to main content

Main menu

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Other Publications
    • NeuroSciences Journal

User menu

  • My alerts
  • Log in

Search

  • Advanced search
Saudi Medical Journal
  • Other Publications
    • NeuroSciences Journal
  • My alerts
  • Log in
Saudi Medical Journal

Advanced Search

  • Home
  • Content
    • Latest
    • Archive
    • home
  • Info for
    • Authors
    • Reviewers
    • Subscribers
    • Institutions
    • Advertisers
    • Join SMJ
  • About Us
    • About Us
    • Editorial Office
    • Editorial Board
  • More
    • Advertising
    • Alerts
    • Feedback
    • Folders
    • Help
  • Follow psmmc on Twitter
  • Visit psmmc on Facebook
  • RSS
Systematic ReviewSystematic Review
Open Access

Prevalence of obesity in treated and untreated patients with attention deficit hyperactivity disorder

A meta-analysis

Fatimah AlAhmari and Mohy Uddin
Saudi Medical Journal August 2022, 43 (8) 873-880; DOI: https://doi.org/10.15537/smj.2022.43.8.20220247
Fatimah AlAhmari
From the Pediatrics Department (AlAhmari), King Faisal Specialist Hospital and Research Centre; and from the Research Quality Management Section (Uddin), King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard - Health Affairs, Riyadh, Kingdom of Saudi Arabia
MD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
Mohy Uddin
From the Pediatrics Department (AlAhmari), King Faisal Specialist Hospital and Research Centre; and from the Research Quality Management Section (Uddin), King Abdullah International Medical Research Center, King Saud bin Abdulaziz University for Health Sciences, Ministry of National Guard - Health Affairs, Riyadh, Kingdom of Saudi Arabia
PhD
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • eLetters
  • Info & Metrics
  • References
  • PDF
Loading

Abstract

Objectives: To discuss and summarize the scholarly published literature on the difference in obesity rate in treated and untreated attention deficit hyperactivity disorder (ADHD) patients to evaluate the influence of ADHD medication on weight status in these individuals.

Methods: PubMed, Cochrane Library, and Google Scholar databases were searched for eligible articles from January to December 2020 using the following medical subject headings (MeSH) terms: “attention deficit hyperactivity disorder and other hyperactivity disorders”, “obesity and overweight”, “obesity treatment”.

Results: A total of 19,449 study participants included in selected 8 studies were assessed with respect to the prevalence of obesity in medicated and unmedicated subgroups of ADHD patients. The total number of ADHD patients with the prescribed medication was 10,279, while the number of unmedicated ADHD patients was 9,170. The odds ratio was 0.65 with a 95% confidence interval of 0.50 to 0.84 favoring regular medical treatment for management of obesity in case of patients with ADHD.

Conclusion: The prevalence of obesity observed in treated ADHD patients was significantly lower compared to that in unmedicated patients. This result suggests that the treatment is not only important for controlling ADHD manifestations but is also associated with lower body mass index. Therefore, further prospective studies with large sample size are required for controlling the confounding factors such as comorbidities and medication status.

Keywords:
  • attention deficit
  • hyperactivity disorder
  • ADHD
  • psychostimulants
  • obesity
  • overweight

Physical health problems are frequently observed in mental health patients compared to the general public.1 Previous studies have confirmed that somatic symptoms significantly contribute to mental health symptoms, and comorbidities play an important role in aggravating primary symptoms, causing physiological impairment, lowering life quality, and enhancing economic burden.2-5 While studying comorbidities of psychiatric and medical diseases, Druss et al6 concluded that approximately 68% of psychiatric patients had one or more somatic disorders. The interlinking of mental and somatic disorders has been understood to a certain extent. For example, mood disorders are seen in hypothyroidism, and schizophrenia and bipolar disorders are associated with metabolic syndrome probably due to that the effect of medication on the development of these complications overrides lifestyle factors.7-9 Moreover, it has been well-observed that most psychiatric patients tend to have unhealthy and unhygienic dietary habits and a sedentary lifestyle.10

Attention deficit hyperactivity disorder (ADHD) has been found to be the most frequent childhood-onset neurodevelopmental disorder, according to the American Psychiatric Association’s DSM-5, it as the presence of 6 or more symptoms in either the inattentive or hyperactive and impulsive domains, or both, that imposes an enormous burden on the population.11,12 It has been reported that impairing symptoms of ADHD in children can persist in adulthood in up to 65% of individuals with a prevalence of ADHD in adulthood of almost 2.5%.13 The study from Jensen et al14 found that 87% of ADHD cases had one comorbidity, and 67% of ADHD cases had more than one comorbidity.Similarly, Bidermanet et al15 stated that 20% of ADHD cases attending clinics had at least 2 comorbidities.All comorbidities seen in ADHD patients could be a manifestation of a single disorder in different ways, or conversely different disorders may have a similar appearance. Therefore, ADHD may be an early manifestation of some other disease or may indicate the development of another disease.15 Specifically, there has been an increasing amount of evidence on possible association between ADHD and obesity/overweight; this association is important when considering ADHD treatment.16,17 The available treatments for ADHD include pharmacological treatments with mainly psychostimulant medications such as methylphenidate, amphetamines, and bupropion.13,18 Most common side effects of these treatments are decreased appetite, headache, abdominal pain, sleep disturbances, and irritability, and less frequent side effects include weight loss, social withdrawal, tics, and emotional modifications in some cases.19

A longitudinal clinical intervention was carried out in 2009 to assess the effects of ADHD drugs on weight change by following 78 severely obese adults diagnosed with ADHD (65 received medication for ADHD and 13 were controls) for 466 days. Its findings revealed that ADHD medication is associated with significant long-term weight loss in patients with a previous history of weight loss failure (12.4% weight loss of initial weight in treated patient versus 2.8% weight gain in untreated patients).20 Similarly, another recent meta-analysis conducted by Cortese et al21 reported that patients receiving medications for ADHD were not at a higher risk for obesity, which was not the case in untreated ADHD patients. Therefore, these studies suggest the importance of stimulant treatment in both managing ADHD symptoms and improving nutritional status in obese ADHD patients.

To elucidate the effect of stimulant pharmacological treatments on nutritional status and weight, it is important to examine the impact of these drugs on ADHD obese patients. The aim of this meta-analysis is to discuss and summarize published scholarly literature on the difference in obesity rate in treated and untreated ADHD patients to evaluate the effect of ADHD medication on weight status in these individuals. The objective is to answer the following question: “Is there a difference in the prevalence between medicated and unmedicated ADHD patients?”

Methods

This study was performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. All studies evaluating the prevalence of obesity in individuals with ADHD were considered to be eligible for inclusion in the meta-analysis. The studies that mentioned the body mass index (BMI) or obesity status of children aged under 18 years, suffering from obesity in association with ADHD with or without prescribed concomitant stimulant medications were also included in the meta-analysis. The following points were considered as the inclusion criteria: studies that evaluated prevalence of obesity in the ADHD population, studies that included medicated and unmedicated ADHD patients, studies that mentioned the BMI status of study participants or obesity in general, and studies with a parallel study design that enrolled both medicated and unmedicated patients suffering from ADHD who were overweight and at risk of developing obesity or who were diagnosed with obesity. The exclusion criteria consisted of: studies that included patients above 18 years of age, studies that included medicated or unmedicated ADHD patients without the other corresponding arm, studies that considered the health outcomes of patients with ADHD but were lacking any comments with respect to body weight and BMI, and studies mentioning the prevalence and control of obesity in individual suffering from autism spectrum disorders (ASD) and other psychological and psychiatric conditions apart from ADHD. The majority of studies that mentioned the prevalence of obesity were cross-sectional and later performed subgroup analysis to ascertain the prevalence and control of obesity in medicated and unmedicated individuals suffering from ADHD along with a few case reports limited to individual findings. Studies that satisfied the selection criteria but were available in the form of abstracts, incomplete studies (such as, those with missing results), duplicates, and unpublished articles were not considered for inclusion in the meta-analysis. Finally, all eligible articles available in English language were selected for evaluation.

Search terminology was defined according to the protocol for identification of the search terms with respect to the prevalence of obesity in medicated and unmedicated individuals with ADHD. The search terms were used with the Boolean operator “AND” to filter the related articles. Free text search utilized the words such as ADHD, treatment, medicated, and unmedicated along with the Boolean operator “OR” in-between them and in association with BMI, obesity, and overweight with the Boolean operator “AND”. In contrast, the controlled language search included the following medical subject headings terms: “attention deficit hyperactivity disorder and other hyperactivity disorders”, “obesity and overweight”, and “obesity treatment”. PubMed, Cochrane Library, and Google Scholar databases were searched for eligible articles from January to December 2020. The reference list of all included studies was further reviewed to include the eligible studies. During the database search for potential studies, titles and abstracts of the articles were screened according to the selection criteria by independent reviewers.

Data was extracted individually and recorded in a customized data extraction sheet by 2 independent reviewers. Discrepancies regarding the inclusion of studies were resolved through discussion or arbitration by involving an additional reviewer, as required. Once the selection of preliminary studies was carried out based on the criteria, full texts of the articles were assessed to evaluate the study content for the meta-analysis. Information pertaining to the prevalence of obesity and the effect of medications on the BMI control was extracted and analyzed. The risk of publication bias assessment was independently performed on each study by 2 reviewers. The overall search process resulted in 1,131 articles, which were reduced to 319 after the removal of duplicates. Eligibility screening yielded 29 studies that were then subjected to full text review. Finally, 8 articles were selected for the meta-analysis.

Statistical analysis

A descriptive analysis of the extracted data was performed. Similar findings from the studies were identified and quantitatively analyzed, which were then represented accordingly. The meta-analysis was performed using the Revman software version 5.3.22 To address the heterogeneity of the included studies with respect to the study population, study environment, and trial setting (which may differ in different clinical trials), the findings from individual studies were pooled using the random effects model, which helped to identify potential areas that could significantly alter the results. Forest plot showing the odds ratio (OR) of the point estimates along with 95% confidence interval (CI) for the prevalence of obesity in medicated and unmedicated individuals with ADHD was constructed and represented accordingly. The degree of heterogeneity among the included studies was evaluated using the I2 test, which acts as a tool to understand the degree to which the studies differ in their clinical trial setting.

Results

After the search and screening process by 2 independent reviewers, a total of 8 studies were selected for meta-analysis.1-8 The details of identification, screening, eligibility, and inclusion of studies is shown in PRISMA flowchart in Figure 1.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1

- Preferred Reporting Items for Systematic Reviews and Meta-Analysis flowchart diagram.

A total of 19,449 study participants included in those 8 studies were assessed with respect to the prevalence of obesity in medicated and unmedicated subgroups of ADHD patients. The total number of ADHD patients with prescribed medication was 10,279, while the sum of unmedicated ADHD patients was 9,170. A total of 359 obese patients were in the medicated subgroup, while 509 obese patients were in the unmedicated group. Five studies1-5 discussed the prevalence of obesity by considering BMI as the criteria for distinction between normal weight and overweight, while remaining 3 studies only described the people who were at risk for developing obesity. The characteristics of the included studies are listed in Table 1.

View this table:
  • View inline
  • View popup
Table 1

- Characteristics of the included studies.

Quality assessment of included studies

The quality of included studies was evaluated using the STROBE guidelines for observational studies.23 Special emphasis was given to the study aim, study participants, clinical trial design, parameters used for assessment of the primary objective, inclusion and exclusion criteria applied for selection of the study sample, treatment arms, variables used for defining the outcome, exposure, and potential confounders and predictors. Methodological quality of the included studies was evaluated to minimize the probability of bias at different points during study selection. The majority of studies scored well in all above mentioned domains; however, there was no formal sample size calculation mentioned in any of the included studies, which limited the overall scoring of all included studies to below 75%.

Prevalence of obesity in ADHD patients

The overall summary estimate of the forest plot (Figure 2) favored the medicated ADHD group to have a low prevalence of obesity.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2

- Forest plot-prevalence of obesity in medicated versus unmedicated attention deficit hyperactivity disorder (ADHD) patients. CI: confidence incterval

Unmedicated ADHD patients were more prone to develop obesity compared to those on treatment for ADHD. The prevalence of obesity was 4 per 100 patients in the medicated subgroup of ADHD (3.5%), while in the case of patients who did not receive any treatment for ADHD, 6 out of 100 patients suffered from obesity (5.6%). The majority of studies recommended adequate medications to be the key factor for obesity control, while 3 studies indicates that ADHD patients with prescribed medications were at equal risk for developing obesity compared to their unmedicated counterparts.1-8 The p-value for overall summary estimate was 0.0009 along with a Z score of 3.33. The odds ratio (OR), calculated using the Mantel–Haenszel random effects model for prevalence of obesity was 0.65 with a 95% CI of 0.50 to 0.84. The combined estimate favored regular medical treatment for management of obesity in case of patients with ADHD because the 95% CI for odds ratio of the summary estimate was completely present on one side of the line of zero effect favoring medicated ADHD group.

Exploration of heterogeneity and publication bias

In addition to the I2 test, Egger’s test was used to assess the heterogeneity of the study. Special precautions were observed to prevent the occurrence of publication bias. The inverted funnel plot (Figure 3) showed a nearly equal representation of studies mentioning obesity to be associated with medicated and unmedicated ADHD patients.

Figure 3
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 3

- Funnel plot-publication bias.

The I2 test’s value of 57% indicated moderate variability among the selected studies. In addition, a major part of 95% CI of individual studies was overlapping with each other, thus representing moderate study variability.

Discussion

Our study findings reported a prevalence rate of obesity of 3.5% in the medicated subgroup of ADHD and 5.6% in patients not receiving any treatment for ADHD. In recent years, several investigations suggested the increased prevalence of ADHD in obese patients and vice versa, and some studies have attempted to explain the reasons for this association. For example, obesity or other risk factors, including fragmented sleep and hypoxemia (due to apneas and hypopneas), may cause excessive daytime sleepiness that in turn contributes to similar ADHD signs and symptoms.32,33 Furthermore, Weinberg and Brumback34 suggested the hypoarousal theory consisting of oversleepiness of ADHD patients compared to controls. Attention deficit hyperactivity disorder patients manifested hyperactivity and impulsivity to stay awake and alert.34 Another study carried out to evaluate sleep and alertness in children with ADHD showed that these patients were sleepier during the day with a deficit in alertness compared to controls.35

Our meta-analysis revealed that the prevalence of obesity observed in treated ADHD patients was significantly lower compared to that in unmedicated ADHD patients, with OR equal to 0.65 with 95% CI of 0.50–0.84, favoring regular medical treatment for management of obesity in case of patients with ADHD. This result was possibly obtained due to the anorectic effects of methylphenidate causing reduced appetite and resulting in weight loss.36 A previous meta-analysis carried out by Cortese et al,21 which included 12 articles, had similar findings yet non-significant results, where patients treated with ADHD medications had rates of obesity that were lower by approximately 40% compared to untreated patients. In addition, the findings of another study,19 which aimed to evaluate the association of treatment duration with weight loss, showed that after comparing patients treated for less than one year with those treated for more than 3 years, these groups had a significant decrease in BMI, showing that BMI tended to decrease without considering the period of treatment. However, the reason for weight loss in all situations has not yet been established, specifically after knowing that the effects of methylphenidate are generally temporary and become less evident during treatment. Strimas et al37 and Davis et al38 suggested that pharmacological treatments are capable of both reducing impulsiveness/inattention and improving inhibitory control, resulting in a decrease in caloric intake with a better and organized diet plan, which in turn may have assisted in weight reduction. However, a naturalistic study by Levy et al20 reported that appetite suppression was evident within 1-1.5 months after starting the treatment, but then it reduced and vanished in the majority of participants within 2 months; the authors concluded that it was not likely that the temporary anorexigenic impact of psychostimulants contributed to the observed weight loss at follow-up >1 year after the start of treatment.

Attention deficit hyperactivity disorder must be presented as the main reason of weight loss failure in the obese population. Patients diagnosed and seeking medical or surgical weight loss must be assessed for ADHD and treated accordingly prior to intervention. Similarly, ADHD patients must be evaluated for possible risk of obesity during their assessment and management. This will result in an improved management outcome and reduced occurrence of post-surgical complications due to poor compliance with diet and supplement requirements.20

Furthermore, a previous systematic review was carried out to assess the effect of physical activity on children with ADHD on the short and long run. Results suggested clinical benefits including alleviated cognitive, behavioural and physical symptoms of ADHD due to exercising.39

Though there are many other databases and indexing services for peer-reviewed literature like PsycINFO, Scopus and Web of Science, but due to our study limitations, we only searched PubMed, Cochrane Library and Google Scholar. This meta-analysis has important clinical and public health implications. Assessing the risk for obesity should be part of the assessment and management of ADHD patients, especially untreated ADHD patients. However, our results showed the following limitations. The publication bias could have occurred from including only studies that were published in English. The analysis excluded unpublished studies that might have been presented at conferences. The analyzed cross-sectional data did not provide deductive conclusions on causality in the association between ADHD medications and obesity status. The definition of obesity in the included studies in children and adolescents was based on different BMI thresholds and definitions, such as Z-scores [85th (at risk for overweight) and 95th percentiles (overweight) of BMI], or BMI adjusted for gender and weight based on WHO’s growth charts and then presented as Z scores.24,27,31 It must be also taken into consideration a re-analysis of the original data (Individual participant data IPD) rather than just extracting aggregated data to allow further subgroups analyses. Most study participants in this analysis were obese; hence, future studies are needed to provide more information on patients with less severe grades of weight excess. Another caveat to this review was that we did not focus on duration of illness and medication use due to the limited number of studies that examined these variables. Finally, the long-term effects of psychostimulants on weight was not fully considered in the present study; weight loss may be related to direct anorexic effects of psychostimulants, or long-term normalization of eating patterns, or other indirect mechanisms.

In conclusion, over the last 3 decades, obesity has become an epidemic posing serious public health issues. In the literature, many studies have assessed the association between ADHD and obesity, and preliminary evidence revealed that the prevalence of obesity observed in treated ADHD patients was significantly lower compared to that in unmedicated patients, suggesting that treatment is associated with lower BMI. Therefore, further prospective studies with large sample size controlling for confounding factors, such as population characteristics including comorbidities and medication status must be investigated further in future research. Moreover, behavioral modification and obesity intervention programs must also take these factors into consideration.

Acknowledgment

The authors gratefully acknowledge SCREBENDI (www.screbendi.com) for the English language editing.

Footnotes

  • Disclosure. Authors have no conflict of interests, and the work was not supported or funded by any drug company.

  • Received April 13, 2022.
  • Accepted June 13, 2022.
  • Copyright: © Saudi Medical Journal

This is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work.

References

  1. 1.↵
    1. de Hert M,
    2. Correll CU,
    3. Bobes J,
    4. Cetkovich-Bakmas M,
    5. Cohen D,
    6. Asai I, et al.
    Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry 2011; 10: 52–77.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Mostafaei S,
    2. Kabir K,
    3. Kazemnejad A,
    4. Feizi A,
    5. Mansourian M,
    6. Hassanzadeh Keshteli A, et al.
    Explanation of somatic symptoms by mental health and personality traits: application of Bayesian regularized quantile regression in a large population study. BMC Psychiatry 2019; 19: 207.
    OpenUrl
  3. 3.
    1. Sartorius N,
    2. Holt RIG,
    3. Maj M
    , editors. Comorbidity of mental and physical disorders. Indian J Med Res 2016; 144: 786–787.
    OpenUrl
  4. 4.
    1. Janse Van Rensburg A,
    2. Dube A,
    3. Curran R,
    4. Ambaw F,
    5. Murdoch J,
    6. Bachmann M, et al.
    Comorbidities between tuberculosis and common mental disorders: a scoping review of epidemiological patterns and person-centred care interventions from low-to-middle income and BRICS countries. Infect Dis Poverty 2020; 9: 4.
    OpenUrl
  5. 5.↵
    1. Kalinin VV
    1. Kutlu A,
    2. Mülayim S
    . Psychiatric Comorbidities and Quality of Life in Epilepsy. In: Kalinin VV, editor. Epileptology The Modern State of Science [Internet]. InTech; 2016 [cited 2021 Feb 6]. Available from: http://www.intechopen.com/books/epileptology-the-modern-state-of-science/psychiatric-comorbidities-and-quality-of-life-in-epilepsy
  6. 6.↵
    1. Druss BG,
    2. Walker ER
    . Mental disorders and medical comorbidity. Synth Proj Res Synth Rep 2011: 1–26.
  7. 7.↵
    1. Menon B
    . Hypothyroidism and bipolar affective disorder: is there a connection? Indian J Psychol Med 2014; 36: 125–128.
    OpenUrl
  8. 8.↵
    1. Chakrabarti S
    . Thyroid functions and bipolar affective disorder. J Thyroid Res 2011; 2011: 306367.
    OpenUrlPubMed
  9. 9.↵
    1. Bly MJ,
    2. Taylor SF,
    3. Dalack G,
    4. Pop-Busui R,
    5. Burghardt KJ,
    6. Evans SJ, et al.
    Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population. Bipolar Disord 2014; 16: 277–288.
    OpenUrlCrossRef
  10. 10.↵
    1. Briguglio M,
    2. Vitale JA,
    3. Galentino R,
    4. Banfi G,
    5. Dina CZ,
    6. Bona A, et al.
    Healthy eating, physical activity, and sleep hygiene (HEPAS) as the winning triad for sustaining physical and mental health in patients at risk for or with neuropsychiatric disorders: considerations for clinical practice. Neuropsychiatr Dis Treat 2020; 16: 55–70.
    OpenUrlPubMed
  11. 11.↵
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th edition. Washington, (DC): American Psychiatric Association Publication; 2013.
  12. 12.↵
    1. Posner J,
    2. Polanczyk GV,
    3. Sonuga-Barke E
    . Attention-deficit hyperactivity disorder. Lancet 2020; 395: 450–462.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Cortese S,
    2. Castellanos FX
    . The relationship between ADHD and obesity: implications for therapy. Expert Rev Neurother 2014; 14: 473–479.
    OpenUrl
  14. 14.↵
    1. Jensen PS,
    2. Martin D,
    3. Cantwell DP
    . Comorbidity in ADHD: implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry 1997; 36: 1065–1079.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Biederman J,
    2. Newcorn J,
    3. Sprich S
    . Comorbidity of attention deficit hyperactivity disorder with conduct, depressive, anxiety, and other disorders. Am J Psychiatry 1991; 148: 564–77.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Cortese S,
    2. Vincenzi B
    . Obesity and ADHD: clinical and neurobiological implications. Curr Top Behav Neurosci 2012; 9: 199–218.
    OpenUrlPubMed
  17. 17.↵
    1. Cortese S,
    2. Faraone SV,
    3. Bernardi S,
    4. Wang S,
    5. Blanco C
    . Adult attention-deficit hyperactivity disorder and obesity: epidemiological study. Br J Psychiatry 2013; 203: 24–34.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Ng QX
    . A Systematic review of the use of bupropion for attention-deficit/hyperactivity disorder in children and adolescents. J Child Adolesc Psychopharmacol 2017; 27: 112–116.
    OpenUrl
  19. 19.↵
    1. Granato MF,
    2. Ferraro AA,
    3. Lellis DM,
    4. Casella EB
    . Associations between attention-deficit hyperactivity disorder (ADHD) Treatment and patient nutritional status and height. Behav Neurol 2018; 2018: e7341529.
    OpenUrl
  20. 20.↵
    1. Levy LD,
    2. Fleming JP,
    3. Klar D
    . Treatment of refractory obesity in severely obese adults following management of newly diagnosed attention deficit hyperactivity disorder. Int J Obes (Lond) 2009; 33: 326–334.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Cortese S,
    2. Moreira-Maia CR
    , St. Fleur D, Morcillo-Peñalver C, Rohde LA, Faraone SV. Association between ADHD and obesity: a systematic review and meta-analysis. Am J Psychiatry 2015; 173: 34–43.
    OpenUrlPubMed
  22. 22.↵
    Cochrane Training. Review Manager (RevMan). [updated 22; cited 2021 Jul 15]. Available from: https://training.cochrane.org/online-learning/core-software-cochrane-reviews/revman
  23. 23.↵
    1. Cuschieri S
    . The STROBE guidelines. Saudi J Anaesth 2019; 13: S31–S34.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Curtin C,
    2. Bandini LG,
    3. Perrin EC,
    4. Tybor DJ,
    5. Must A
    . Prevalence of overweight in children and adolescents with attention deficit hyperactivity disorder and autism spectrum disorders: a chart review. BMC Pediatr 2005; 5: 48.
    OpenUrlCrossRefPubMed
  25. 25.
    1. Visser SN,
    2. Lesesne CA,
    3. Perou R
    . National estimates and factors associated with medication treatment for childhood attention-deficit/hyperactivity disorder. Pediatrics 2007; 119: S99–S106.
    OpenUrlAbstract/FREE Full Text
  26. 26.
    1. Waring ME,
    2. Lapane KL
    . Overweight in children and adolescents in relation to attention-deficit/hyperactivity disorder: results from a national sample. Pediatrics 2008; 122: e1–e6.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Dubnov-Raz G,
    2. Perry A,
    3. Berger I
    . Body mass index of children with attention-deficit/hyperactivity disorder. J Child Neurol 2011; 26: 302–308.
    OpenUrlCrossRefPubMed
  28. 28.
    1. Kim J,
    2. Mutyala B,
    3. Agiovlasitis S,
    4. Fernhall B
    . Health behaviors and obesity among US children with attention deficit hyperactivity disorder by gender and medication use. Prev Med 2011; 52: 218–222.
    OpenUrlCrossRefPubMed
  29. 29.
    1. Byrd HCM,
    2. Curtin C,
    3. Anderson SE
    . Attention-deficit/hyperactivity disorder and obesity in US males and females, age 8-15 years: National Health and Nutrition Examination Survey 2001-2004. Pediatr Obes 2013; 8: 445–453.
    OpenUrl
  30. 30.
    1. Spencer TJ,
    2. Faraone SV,
    3. Tarko L,
    4. McDermott K,
    5. Biederman J
    . Attention-deficit/hyperactivity disorder and adverse health outcomes in adults. J Nerv Ment Dis 2014; 202: 725–731.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Hanć T,
    2. Słopień A,
    3. Wolańczyk T,
    4. Dmitrzak-Węglarz M,
    5. Szwed A,
    6. Czapla Z, et al.
    ADHD and overweight in boys: cross-sectional study with birth weight as a controlled factor. Eur Child Adolesc Psychiatry 2015; 24: 41–53.
    OpenUrl
  32. 32.↵
    1. Cortese S,
    2. Konofal E,
    3. Bernardina BD,
    4. Mouren MC,
    5. Lecendreux M
    . Does excessive daytime sleepiness contribute to explaining the association between obesity and ADHD symptoms? Med Hypotheses 2008; 70: 12–16.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Gami AS,
    2. Caples SM,
    3. Somers VK
    . Obesity and obstructive sleep apnea. Endocrinol Metab Clin North Am 2003; 32: 869–894.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Weinberg WA,
    2. Brumback RA
    . Primary disorder of vigilance: a novel explanation of inattentiveness, daydreaming, boredom, restlessness, and sleepiness. J Pediatr 1990; 116: 720–725.
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Lecendreux M,
    2. Konofal E,
    3. Bouvard M,
    4. Falissard B,
    5. Mouren-Siméoni MC
    . Sleep and alertness in children with ADHD. J Child Psychol Psychiatry 2000; 41: 803–812.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Barkley RA,
    2. McMurray MB,
    3. Edelbrock CS,
    4. Robbins K
    . Side effects of metlyiphenidate in children with attention deficit hyperactivity disorder: a systemic, placebo-controlled evaluation. Pediatrics 1990; 86: 184–192.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Strimas R,
    2. Davis C,
    3. Patte K,
    4. Curtis C,
    5. Reid C,
    6. McCool C
    . Symptoms of attention-deficit/hyperactivity disorder, overeating, and body mass index in men. Eat Behav 2008; 9: 516–518.
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Davis C,
    2. Levitan RD,
    3. Smith M,
    4. Tweed S,
    5. Curtis C
    . Associations among overeating, overweight, and attention deficit/hyperactivity disorder: a structural equation modelling approach. Eat Behav 2006; 7: 266–274.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Ng QX,
    2. Ho CYX,
    3. Chan HW,
    4. Yong BZJ,
    5. Yeo WS
    . Managing childhood and adolescent attention-deficit/hyperactivity disorder (ADHD) with exercise: A systematic review. Complement Ther Med 2017; 34: 123–128.
    OpenUrl
PreviousNext
Back to top

In this issue

Saudi Medical Journal: 43 (8)
Saudi Medical Journal
Vol. 43, Issue 8
1 Aug 2022
  • Table of Contents
  • Cover (PDF)
  • Index by author
Print
Download PDF
Email Article

Thank you for your interest in spreading the word on Saudi Medical Journal.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prevalence of obesity in treated and untreated patients with attention deficit hyperactivity disorder
(Your Name) has sent you a message from Saudi Medical Journal
(Your Name) thought you would like to see the Saudi Medical Journal web site.
Citation Tools
Prevalence of obesity in treated and untreated patients with attention deficit hyperactivity disorder
Fatimah AlAhmari, Mohy Uddin
Saudi Medical Journal Aug 2022, 43 (8) 873-880; DOI: 10.15537/smj.2022.43.8.20220247

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Prevalence of obesity in treated and untreated patients with attention deficit hyperactivity disorder
Fatimah AlAhmari, Mohy Uddin
Saudi Medical Journal Aug 2022, 43 (8) 873-880; DOI: 10.15537/smj.2022.43.8.20220247
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgment
    • Footnotes
    • References
  • Figures & Data
  • eLetters
  • References
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Breast cancer incidence after hormonal treatment for infertility
  • Pocket-creation method versus conventional method of endoscopic submucosal dissection for early gastric cancer
  • Advancing genetic counselling in Southern Africa
Show more Systematic Review

Similar Articles

Keywords

  • attention deficit
  • hyperactivity disorder
  • ADHD
  • psychostimulants
  • obesity
  • overweight

CONTENT

  • home

JOURNAL

  • home

AUTHORS

  • home
Saudi Medical Journal

© 2025 Saudi Medical Journal Saudi Medical Journal is copyright under the Berne Convention and the International Copyright Convention.  Saudi Medical Journal is an Open Access journal and articles published are distributed under the terms of the Creative Commons Attribution-NonCommercial License (CC BY-NC). Readers may copy, distribute, and display the work for non-commercial purposes with the proper citation of the original work. Electronic ISSN 1658-3175. Print ISSN 0379-5284.

Powered by HighWire